UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Regulatory (FoxP3 + ) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Scientific reports, 2020-11, Vol.10 (1), p.18994, Article 18994

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

Oncoimmunology, 2020-01, Vol.9 (1), p.1722023

2020

Link zum Volltext

Verfügbarkeit prüfen

PD-1 blockade-unresponsive human tumor-infiltrating CD8 + T cells are marked by loss of CD28 expression and rescued by IL-15

Cellular & molecular immunology, 2021-02, Vol.18 (2), p.385-397

2021

Link zum Volltext

Verfügbarkeit prüfen

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS -mutant non-small cell lung cancer

Oncotarget, 2017-09, Vol.8 (40), p.67526-67537

2017

Link zum Volltext

Verfügbarkeit prüfen

Susceptibility of CD24+ ovarian cancer cells to anti-cancer drugs and natural killer cells

Biochemical and biophysical research communications, 2012-10, Vol.427 (2), p.373-378

2012

Link zum Volltext

Verfügbarkeit prüfen

The First-week Proliferative Response of Peripheral Blood PD-1 + CD8 + T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Clinical cancer research, 2019-04, Vol.25 (7), p.2144-2154

2019

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial

Journal of thoracic oncology, 2022-07, Vol.17 (7), p.900-908

2022

Link zum Volltext

Verfügbarkeit prüfen

MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

European journal of immunology, 2020-11, Vol.50 (11), p.1810-1819

2020

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model

Nanomedicine, 2021-10, Vol.37, p.102415-102415, Article 102415

2021

Link zum Volltext

Verfügbarkeit prüfen

Correction: The First-week Proliferative Response of Peripheral Blood PD-1 + CD8 + T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Clinical cancer research, 2020-12, Vol.26 (24), p.6610-6610

2020

Link zum Volltext

Verfügbarkeit prüfen

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

Oncotarget, 2016-03, Vol.7 (12), p.14803-14813

2016

Link zum Volltext

Verfügbarkeit prüfen

INF-γ production of NK cells is suppressed in cancer patients. (45.10)

The Journal of immunology (1950), 2012-05, Vol.188 (1_Supplement), p.45-45.10

2012

Link zum Volltext

Verfügbarkeit prüfen

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

Clinical cancer research, 2016-05, Vol.22 (9), p.2139-2145

2016

Link zum Volltext

Verfügbarkeit prüfen

Extracellular heat‐shock protein 90 down‐regulates NK cell immune responses

The FASEB journal, 2012-04, Vol.26 (S1)

2012

Link zum Volltext

Verfügbarkeit prüfen

Severe immune-related adverse events in anti-PD-1-treated patients are clustered into distinct subtypes by peripheral blood T-cell profiles

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2564-2564

2019

Link zum Volltext

Verfügbarkeit prüfen

Su1528 RISING PREVALENCE AND LONGITUDINAL EFFECTS ON MORTALITY BASED ON SPECTRUM OF ALCOHOL INTAKE IN STEATOTIC LIVER DISEASE (MASLD, METALD AND ALD). A US POPULATION STUDY

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1625-S-1625

2024

Link zum Volltext

Verfügbarkeit prüfen

Monitoring peripheral blood PD-1 + CD8 + T cells to predict response to anti-PD-1 therapy in solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e24115-e24115

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2837: The CDK4/6 inhibitor has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2837-2837

2016

Link zum Volltext

Verfügbarkeit prüfen

Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e14118-e14118

2016

Link zum Volltext

Verfügbarkeit prüfen

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells

Investigational new drugs, 2016-08, Vol.34 (4), p.407-415

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8086-8086

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract A138: CD39 increase on cytotoxic T-cell induced by myeloid-derived suppressor cell correlated with poor prognosis in patients with non-small cell lung cancer

Cancer immunology research, 2019-02, Vol.7 (2_Supplement), p.A138-A138

2019

Link zum Volltext

Verfügbarkeit prüfen

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells

Investigational new drugs, 2016-08, Vol.34 (4), p.407-415

2016

Link zum Volltext

Verfügbarkeit prüfen

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR super(L858R/T790M) in non-small cell lung cancer cells

Investigational new drugs, 2016-08, Vol.34 (4), p.407-415

2016

Link zum Volltext

Verfügbarkeit prüfen

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR^sup L858R/T790M^ in non-small cell lung cancer cells

Investigational new drugs, 2016-08, Vol.34 (4), p.407

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(30)

Sprache

Englisch
(28)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Life Sciences & Biomedicine
(11)
Humans
(9)
Female
(8)
Oncology
(8)
Adult
(4)
Aged
(4)
Animals
(4)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(4)
Carcinoma, Non-Small-Cell Lung - Metabolism
(4)
Cd8-Positive T-Lymphocytes - Immunology
(4)
Immunotherapy
(4)
Lung Cancer
(4)
Lung Neoplasms - Drug Therapy
(4)
Lung Neoplasms - Metabolism
(4)
Male
(4)
Middle Aged
(4)
Aged, 80 And Over
(3)
Apoptosis
(3)
Cell Biology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Regulatory (FoxP3 + ) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

PD-1 blockade-unresponsive human tumor-infiltrating CD8 + T cells are marked by loss of CD28 expression and rescued by IL-15

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS -mutant non-small cell lung cancer

Susceptibility of CD24+ ovarian cancer cells to anti-cancer drugs and natural killer cells

The First-week Proliferative Response of Peripheral Blood PD-1 + CD8 + T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial

MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model

Correction: The First-week Proliferative Response of Peripheral Blood PD-1 + CD8 + T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

INF-γ production of NK cells is suppressed in cancer patients. (45.10)

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

Extracellular heat‐shock protein 90 down‐regulates NK cell immune responses

Severe immune-related adverse events in anti-PD-1-treated patients are clustered into distinct subtypes by peripheral blood T-cell profiles

Su1528 RISING PREVALENCE AND LONGITUDINAL EFFECTS ON MORTALITY BASED ON SPECTRUM OF ALCOHOL INTAKE IN STEATOTIC LIVER DISEASE (MASLD, METALD AND ALD). A US POPULATION STUDY

Monitoring peripheral blood PD-1 + CD8 + T cells to predict response to anti-PD-1 therapy in solid tumors

Abstract 2837: The CDK4/6 inhibitor has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells

A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib

Abstract A138: CD39 increase on cytotoxic T-cell induced by myeloid-derived suppressor cell correlated with poor prognosis in patients with non-small cell lung cancer

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR super(L858R/T790M) in non-small cell lung cancer cells

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR^sup L858R/T790M^ in non-small cell lung cancer cells

Suchergebnisse filtern